Trends in Cardiovascular Medicine最新文献_第5页

Transcatheter procedures for tricuspid regurgitation in advanced heart failure: A systematic review 经导管治疗晚期心力衰竭三尖瓣反流：系统回顾。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-10-22 DOI: 10.1016/j.tcm.2025.10.007

Christos Kourek , Serge Sicouri , Dimitrios E Magouliotis , Andrew Xanthopoulos , Basel Ramlawi

{"title":"Transcatheter procedures for tricuspid regurgitation in advanced heart failure: A systematic review","authors":"Christos Kourek , Serge Sicouri , Dimitrios E Magouliotis , Andrew Xanthopoulos , Basel Ramlawi","doi":"10.1016/j.tcm.2025.10.007","DOIUrl":"10.1016/j.tcm.2025.10.007","url":null,"abstract":"<div><div>Tricuspid regurgitation (TR) in advanced heart failure (HF) is associated with poor prognosis, functional decline, and increased morbidity. This systematic review synthesizes current evidence of transcatheter device tricuspid transcatheter approaches in advanced HF patients. A comprehensive search of PubMed, Embase, Scopus, CINAHL, and the Cochrane Library identified studies evaluating transcatheter procedures for moderate-to-severe TR in advanced HF, and reporting procedural outcomes, survival, and functional measures. A total of 37 studies encompassing approximately 2,372 patients were included, spanning edge-to-edge repair systems (TriClip, PASCAL), annuloplasty devices (Cardioband, Trialign, TriCinch), transcatheter valve replacement (Evoque, LuX-Valve, NaviGate, Intrepid), heterotopic caval valve implantation (TricValve, Tricento), and leaflet spacers (FORMA). Most patients were in NYHA class III–IV with high surgical risk scores. Across techniques, procedural success rates were high, with consistent reductions in TR severity and improvements in NYHA class, 6-minute walk distance, and quality-of-life scores. Edge-to-edge repair was the most frequently studied, showing favorable safety and symptom improvement. Mortality rates varied, with limited long-term follow-up data. Transcatheter interventions for TR in advanced HF offer promising improvements in symptoms, functional status, and quality of life. Given patient and anatomical heterogeneity, an individualized approach is essential.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"36 4","pages":"Pages 204-215"},"PeriodicalIF":9.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-genetic factors and their impact on severity of inherited cardiomyopathies: Tipping the balance 非遗传因素及其对遗传性心肌病严重程度的影响：打破平衡。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-11-12 DOI: 10.1016/j.tcm.2025.11.003

Joanna Sweeting, Fergus Stafford, Sophie Hespe, Alexandra Butters, Jodie Ingles

{"title":"Non-genetic factors and their impact on severity of inherited cardiomyopathies: Tipping the balance","authors":"Joanna Sweeting, Fergus Stafford, Sophie Hespe, Alexandra Butters, Jodie Ingles","doi":"10.1016/j.tcm.2025.11.003","DOIUrl":"10.1016/j.tcm.2025.11.003","url":null,"abstract":"<div><div>Inherited cardiomyopathies are a diverse group of diseases with overlapping clinical features and genetic basis. Once thought to be primarily monogenic diseases, it is now known that disease severity and penetrance can be impacted by both genetic and non-genetic factors, such as comorbidities. Inherited cardiomyopathies include hypertrophic (HCM), dilated (DCM), arrhythmogenic (ACM) and restrictive cardiomyopathies (RCM). Although many causative genes have been identified for these conditions, a monogenic cause cannot be discovered in many cases, and other factors play a role. Moreover, the clinical heterogeneity observed cannot be explained by a single variant, even when one has been identified.</div><div>Here we review non-genetic factors, including presence of concomitant conditions such as obesity, hypertension, sleep apnea, diabetes and pregnancy, in addition to the impact of lifestyle behaviours such as physical activity and drug taking. Further, we summarise the role of common variants in tipping the balance on disease penetrance and/or severity.</div><div>Clinical considerations and opportunities to improve outcomes in inherited cardiomyopathies will be examined, with a particular focus on the potential to reduce disease severity or even prevent disease onset, through lifestyle modification and recognition of non-genetic contributing factors.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"36 4","pages":"Pages 247-254"},"PeriodicalIF":9.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial commentary: Free fall: Cardiometabolic disturbances, cancer and its treatment 自由落体：心脏代谢紊乱、癌症及其治疗。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-11-21 DOI: 10.1016/j.tcm.2025.11.005

Jordan C. Ray , Joerg Herrmann

引用次数: 0

Editorial Commentary: The dilemma of primary prevention in coronary artery diseases: a call for action 冠心病初级预防的困境：行动呼吁

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-12-05 DOI: 10.1016/j.tcm.2025.12.001

Pietro Scicchitano

引用次数: 0

Gene editing for inherited cardiac conditions: A new frontier in cardiology 遗传性心脏病的基因编辑：心脏病学的新前沿。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-11-12 DOI: 10.1016/j.tcm.2025.11.002

Toufik Abdul-Rahman , Poulami Roy , Neil Garg , Abubakar Nazir , Kahan Samirkumar Mehta , Neel Ajit Doshi , Shamaila Hassnain , Renitha Reddi , Sai Gautham Kanagala , Patrick Ashinze , Carl J. Lavie , Rahul Gupta

{"title":"Gene editing for inherited cardiac conditions: A new frontier in cardiology","authors":"Toufik Abdul-Rahman , Poulami Roy , Neil Garg , Abubakar Nazir , Kahan Samirkumar Mehta , Neel Ajit Doshi , Shamaila Hassnain , Renitha Reddi , Sai Gautham Kanagala , Patrick Ashinze , Carl J. Lavie , Rahul Gupta","doi":"10.1016/j.tcm.2025.11.002","DOIUrl":"10.1016/j.tcm.2025.11.002","url":null,"abstract":"<div><div>Inherited cardiac conditions (ICCs) such as hypertrophic cardiomyopathy and Marfan syndrome pose significant global health challenges, often rooted in complex genetic mutations. Recent advances in gene editing, particularly the CRISPR/Cas9 system, have opened new avenues for precise, personalized interventions. This review examines the current landscape of gene editing in cardiology, with emphasis on its scientific promise, integration with epigenetics, gene therapy, and artificial intelligence, and its potential to transform clinical outcomes. Key gene editing strategies are analyzed for their efficacy and translational potential. The review also explores ongoing clinical trials and emerging research, offering practical insights for future studies. Ethical implications are critically evaluated, with proposed frameworks to address concerns around safety, equity, and long-term consequences. By synthesizing these developments, this review underscores the urgent need for continued interdisciplinary research in the quest to mitigate inherited cardiac diseases.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"36 4","pages":"Pages 232-244"},"PeriodicalIF":9.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management SGLT2抑制剂在心力衰竭治疗中的作用机制和临床前景。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-11-16 DOI: 10.1016/j.tcm.2025.11.004

Samin Sadeghi Vahid , Marziyeh Salehi Jahromi , George V. Moukarbel , Jennifer W. Hill

{"title":"Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management","authors":"Samin Sadeghi Vahid , Marziyeh Salehi Jahromi , George V. Moukarbel , Jennifer W. Hill","doi":"10.1016/j.tcm.2025.11.004","DOIUrl":"10.1016/j.tcm.2025.11.004","url":null,"abstract":"<div><div>Sodium–glucose co-transporter-2 (SGLT2) inhibitors have become a cornerstone of heart-failure (HF) therapy, lowering hospitalization and cardiovascular mortality in patients with and without diabetes across the spectrum of ejection-fraction phenotypes. Their cardioprotective effects extend beyond glycemic control and are best explained by a hierarchy of mechanisms initiated in the kidney. Early tubular inhibition restores tubuloglomerular feedback, producing osmotic diuresis, natriuresis, and modest reductions in plasma volume and blood pressure that together relieve ventricular preload and afterload. These renal and hemodynamic actions are followed by sustained adaptations involving neurohormonal modulation, erythropoiesis, improved cortical oxygenation, and progressive anti-inflammatory, antifibrotic, and mitochondrial effects. Through these interrelated pathways, SGLT2 inhibition preserves kidney function, limits congestion, and promotes cardiac reverse remodeling. Recognizing that these mechanisms act sequentially and in parallel clarifies how SGLT2 inhibitors complement standard therapies and guides ongoing mechanistic studies to refine their role in HF management.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"36 4","pages":"Pages 193-201"},"PeriodicalIF":9.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145551748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary imaging-based approach to primary prevention of coronary artery disease 冠状动脉疾病初级预防的现代影像学方法。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-12-03 DOI: 10.1016/j.tcm.2025.11.007

Susan K. Keen, Milind Y. Desai

引用次数: 0

Editorial commentary: The song remains the same but the impact depends upon genetics 这首歌仍然是一样的，但影响取决于基因。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2026-05-01 Epub Date: 2025-12-27 DOI: 10.1016/j.tcm.2025.12.007

Clarissa Savko, Mark Sussman

引用次数: 0

Editorial commentary: Percutaneous therapies for severe tricuspid regurgitation in advanced symptomatic disease 晚期症状性疾病严重三尖瓣反流的经皮治疗。